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Trypanosoma brucei brucei is the causative agent of nagana in cattle and can infect a wide range of mammals
but is unable to infect humans because it is susceptible to the innate cytotoxic activity of normal human serum.
A minor subfraction of human high-density lipoprotein (HDL) containing apolipoprotein A-I (apoA-I), apo-
lipoprotein L-I (apoL-I), and haptoglobin-related protein (Hpr) provides this innate protection against T. b.
brucei infection. This HDL subfraction, called trypanosome lytic factor (TLF), kills T. b. brucei following
receptor binding, endocytosis, and lysosomal localization. Trypanosoma brucei rhodesiense, which is morpho-
logically and physiologically indistinguishable from T. b. brucei, is resistant to TLF-mediated killing and causes
human African sleeping sickness. Human infectivity by T. b. rhodesiense correlates with the evolution of a
resistance-associated protein (SRA) that is able to ablate TLF killing. To examine the mechanism of TLF
resistance, we transfected T. b. brucei with an epitope-tagged SRA gene. Transfected T. b. brucei expressed SRA
mRNA at levels comparable to those in T. b. rhodesiense and was highly resistant to TLF. In the SRA-
transfected cells, intracellular trafficking of TLF was altered, with TLF being mainly localized to a subset of
SRA-containing cytoplasmic vesicles but not to the lysosome. These results indicate that the cellular distri-
bution of TLF is influenced by SRA expression and may directly determine the organism’s susceptibility to
TLF.
Humans are resistant to infections by Trypanosoma brucei
brucei, which can infect cattle and wild animals (4, 35, 48). This
innate resistance to T. b. brucei is mediated by a subfraction of
human high-density lipoprotein (HDL), termed trypanosome
lytic factor (TLF), which represents 0.5% of the total serum
HDL (21, 38, 39, 45, 46). The protein composition of TLF was
recently elucidated by mass spectroscopy and biochemical re-
constitution, and it was found to be composed of apolipopro-
tein A-I (apoA-I), apoL-I, and Hpr (13, 29, 43). In human
serum, these proteins are colocalized within spherical particles
containing phospholipids and cholesterol. When isolated from
human HDL, both Hpr and apoL-I are toxic to T. b. brucei;
however, reconstitution of these proteins into the same HDL
particle increases the specific activity of trypanosome killing
approximately 10-fold (43). In human serum, 99% of the
trypanolytic activity is associated with native HDLs containing
both Hpr and apoL-I. Furthermore, the specific activity of this
HDL subclass for T. b. brucei killing is several hundredfold
higher than those of HDLs containing Hpr or apoL-I alone
(43). The synergism of Hpr and apoL-I may be critical for the
sterile innate immunity humans have against T. b. brucei infec-
tion.
The cellular pathway for TLF killing of T. b. brucei requires
high-affinity binding to cell surface receptors in the flagellar
pocket, followed by endocytosis and routing to the lysosome
(12, 19, 20, 26, 44). Interruption of trafficking to or acidification
of the lysosome spares T. b. brucei from TLF killing. The
biochemical events that occur within the lysosome, eventually
leading to trypanosome lysis, may be complicated since multi-
ple toxins are present in the TLF particle. Two potential mech-
anisms for TLF killing have been proposed. The first model
proposes that within the acidic lysosome, TLF is able to accel-
erate the reduction of Fe3, resulting in the formation of
reactive free radicals, lipid peroxidation, and eventually, lyso-
somal membrane destabilization (3). The second model is
based on studies with recombinant apoL-I which demonstrate
that apoL-I is able to form anion channels in vitro, and when
taken up by T. b. brucei, triggers depolarization of the lysoso-
mal membrane, leading to an influx of chloride and subsequent
osmotic swelling of the lysosome until the trypanosome lyses
(36). The recent report that TLF can form cation-selective
pores in unilamellar vesicles is consistent with a pore-forming
mechanism for trypanosome killing (33). The identification of
two toxins within the same native HDL raises the interesting
possibility that the two proposed mechanisms may work in
concert to provide the synergism observed with native and
reconstituted HDL containing Hpr and apoL-I (43). Despite
the uncertainties concerning the precise mechanism of killing,
there is general agreement that localization of TLF to the
lysosome is a prerequisite step (32, 47).
Resistance to the cytotoxic activities of normal human serum
has been recognized as the key feature distinguishing T. b.
brucei from the human pathogen T. b. rhodesiense. Human
serum resistance in all isolates of T. b. rhodesiense coincides
with the expression of the serum resistance-associated gene
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(SRA) (8, 9, 10, 31, 40, 51, 37, 49). SRA is a member of the
variable surface glycoprotein (VSG) family of proteins in Af-
rican trypanosomes, and despite having low sequence homol-
ogy (25%) with VSGs, it shares several sequence and struc-
tural features with VSGs (6, 9, 11). SRA is an expression
site-associated gene in T. b. rhodesiense and is located up-
stream of the VSG in the active telomeric expression site (51).
The role of SRA in resistance to human serum was conclu-
sively shown in transfection studies of T. b. brucei with SRA
(50, 51). These studies were extended to show that recombi-
nant apoL-I and SRA bind in vitro by a coiled-coil interaction
between the two proteins, and this has been proposed to di-
rectly inhibit trypanosome killing by apoL-I (47). Immunoflu-
orescence microscopy analysis of T. b. rhodesiense indicated
that apoL-I and SRA colocalized to the lysosome in trypano-
somes treated with apoL-I. However, other studies have shown
that TLF uptake and cellular localization differed in resistant
and susceptible lines of T. b. rhodesiense (19). TLF accumula-
tion was reduced approximately sixfold in resistant trypano-
somes, and the cell-associated TLF was excluded from the
lysosome (19). This indicated that differences in cellular traf-
ficking of TLF might contribute to trypanosome susceptibility
to TLF killing.
Here we show that transfection of SRA into three different
bloodstream-stage T. b. brucei isolates expressing different
VSGs was sufficient to confer high levels of resistance to TLF
and human serum. Epitope-tagged SRA also conferred TLF
resistance and allowed subcellular localization of SRA to non-
lysosomal vesicles predominantly located between the nucleus
and the kinetoplast. In SRA-expressing cells, TLF was not
routed to the lysosome, and colocalization of TLF and SRA
was observed in small cytoplasmic vesicles. Based on these
observations, we conclude that the association of SRA with
TLF-containing endosomes results in rerouting of TLF, thus
preventing lysosomal localization and trypanosome death.
MATERIALS AND METHODS
Trypanosome isolates and culture methods. Culture-adapted monomorphic
isolates of T. b. brucei MiTat 1.2 (427/221), pleomorphic BiTat 1.1 (KETRI 667),
and GuTat 10.1 (TREU 927/4) cells were used throughout these studies. Blood-
stream-stage cultures were grown in HMI-9 medium supplemented with 10%
fetal bovine serum (FBS; HyClone, Logan, UT) and 10% Serum Plus (JRH
Bioscience, Lenexa, KS) (22).
Cloning of Ty epitope-tagged SRA and transfection of T. b. brucei. The DNA
sequence encoding the Ty epitope, containing the coding information for a
10-amino-acid sequence of the major structural protein of the Saccharomyces
cerevisiae Ty1 virus-like particle, was inserted within the coding sequence of the
SRA cDNA (accession no. AF097331). The oligomers Ty-5 and Ty-3 were
synthesized with a HindIII overhang (Ty-5, AGCTTGAGGTCCATACTAAC
CAGCATCCACTTGAC; Ty-3, AGCTTGTCAAGTGGATCCTGGTTAGTA
TGGACCTC [the HindIII overhang is shown with underlining]), annealed, and
cloned into a unique HindIII site at position 848 in the SRA gene. SRA, with and
without the epitope tag, was PCR amplified with the Expand High Fidelity PCR
system (Roche Molecular Biochemicals, Indianapolis, IN), using primers 5SRA
and 3SRA with EcoRI sites (5SRA, CCCGAATTCGTAACAGCAATGCCCC
GAAATTCGGGC; 3SRA, CCCGAATTCGTGAAAATTAAAACAGAAA
GGCC [EcoRI sites are shown with underlining; the positions of the ATG start
codon and the TTA termination codon are indicated in boldface]). Digested
PCR products were cloned into the trypanosome expression vector pURAN (25).
SRA was targeted to a small polycistronic transcription unit containing the
neomycin resistance gene downstream. The multiple cloning site was flanked by
tubulin intergenic regions to ensure accurate and efficient processing of the
transcript. Prior to transfection, the vector was linearized at a unique SunI
(isoschizomer of BsiW1) site of the ribosomal promoter sequence to allow
efficient insertion into the endogenous rRNA gene locus (25).
For transfections of bloodstream-stage trypanosomes, cells were resuspended
at 3  107 cells/ml in Cytomix (120 mM KCl, 150 M CaCl2, 10 mM phosphate
buffer, pH 7.6, 25 mM HEPES, pH 7.6, 5 mM MgCl2, 2 mM EGTA, pH 7.6).
Cells (1.2  106) were mixed with 30 g of linearized DNA and electroporated
(GenePulser II; Bio-Rad Laboratories, Richmond, CA) in a 0.4-cm GenePulser
cuvette (Bio-Rad 165-2088) at 1.5 kV, 25 F, and 200 . Electroporated cells
were allowed to recover for 24 h in HMI-9 medium before the addition of 2.5
g/ml Geneticin (G418 sulfate). Drug-resistant populations were cloned, grown
on agarose plates containing 2 g/ml G418, and subsequently maintained in
HMI-9 medium with constant drug selection (7).
Purification of trypanolytic HDLs and in vitro lysis assays. Normal human
blood was obtained from healthy fasting donors. Lytic HDLs were purified as
described previously, and aliquots were frozen at 70°C (21). One unit of lytic
activity is defined as the amount of HDL needed to kill 50% of human-serum-
susceptible T. b. brucei (IlTat 1.3) organisms in a standard 2-h lysis assay at 37°C
(21). Typically, 0.01 g of purified TLF provided a unit of trypanolytic activity in
this in vitro assay (43). Lysis assays performed with cultured cells were extended
to 4 h. The percentage of lysed cells was counted among 100 cells. Growth
inhibition assays were performed by the addition of human serum (50%) to
cultured bloodstream-stage trypanosomes. After 24 h, the percentage of cells
surviving was determined by phase-contrast microscopy.
To estimate the growth rates of wild-type and transfected trypanosomes, cells
were inoculated at 1  104 cells/ml in HMI-9 medium and counted daily until
stationary phase was reached. The growth rate was calculated with the following
equation: 1/v 	 [log10 2 (T  T0)]/(log10 N  log10 N0).
DNA and RNA analysis. Genomic DNA was isolated as described previously
(30). Twenty nanograms of genomic DNA was used for PCRs to examine the
presence of SRA (5 primer, CACACCTCTAAGAATCACAATAG; 3 primer,
AATTCATGAAAATGTGTTAAAG) and tubulin (5 primer, CCGTGGCAT
ATGGCAAG; 3 primer, GGGGGTGCACTTTGTC) gene sequences. South-
ern blots were performed according to standard protocols (42). Total RNA was
isolated with Trizol reagent (Roche Biochemicals, Indianapolis, IN), and 5 g of
RNA was separated in 1% formaldehyde gels and electroblotted at 15 V for 1 h,
followed by 50 V for 1.5 h, onto a positively charged nylon membrane (Roche
Biochemicals, Indianapolis, IN). DNA probes were labeled by the random
primer method (Life Technologies-Invitrogen, Carlsbad, CA) with [32P]dCTP.
The blots were hybridized in 0.9 M NaCl, 5 Denhardt’s solution, 10% dextran
sulfate, 5 mM EDTA, 0.1% sodium dodecyl sulfate [SDS], 40% formamide, 0.1
mg/ml salmon sperm DNA overnight at 42°C and subsequently washed at 60°C
with 2 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 1% SDS, and
finally 0.1 SSC, 1% SDS at room temperature. Alternatively, the probes were
labeled with AlkPhos Direct (Amersham Pharmacia, Piscataway, NJ), hybrid-
ized, and developed according to the manufacturer’s description.
Analysis of SRA by SDS-PAGE and Western blotting. Cultured cells were
washed twice with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl,
4.3 mM KH2PO4, 1.4 mM Na2HPO4) and then resuspended in lysis buffer (100
mM Tris, pH 8; 10 mM EDTA; 0.5% SDS) containing a protease inhibitor
cocktail (Complete Mini; Roche Biochemicals, Indianapolis, IN). Freshly pre-
pared cell lysates (equivalent to 3  106 cells per lane) were separated in 10%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels (24). Proteins were
transferred to nitrocellulose membranes (0.2-m Protran; Schleicher and
Schuell, Dassel, Germany) for 45 min at 57 V. Polyclonal antibodies against VSG
221 were added at a 1:2,000 dilution, incubated for 1 h at room temperature, and
developed according to a standard protocol (5). The monoclonal antibodies
against the Ty epitope (immunoglobulin G1 subtype) are specific to the epitope
tag and have previously been shown to have no cross-reactivity with procyclic
trypanosome proteins (2). These antibodies were incubated with protein blots
overnight at a 1:5 dilution and developed with BCIP/NBT (5-bromo-4-chloro-3-
indolylphosphate/Nitro Blue Tetrazolium) under standard conditions. BB2 hy-
bridoma cells expressing antibodies against the Ty epitope were generously
provided by Keith Gull, University of Oxford, United Kingdom.
Cellular localization of SRA and TLF. Cultured bloodstream-stage trypano-
somes were collected by centrifugation at 2,000  g for 10 min, washed in PBS
containing 1% glucose (PBSG), resuspended in PBS–10% FBS at 3  107
cells/ml, and smeared onto a microscope slide. After being air dried, cells were
fixed in cold methanol for 10 min at 4°C. Cells were rehydrated in PBS–10% FBS
and subsequently incubated in PBS–10% FBS with anti-Ty (1:50 dilution) for 1 h
at room temperature. Slides were washed with PBS, and Alexa Fluor 488-labeled
goat anti-mouse immunoglobulin G (Molecular Probes, Eugene, OR) was added
at a 1:1,000 dilution in PBS–10% FBS for 1 h at room temperature. 4,6-
Diamidino-2-phenylindole (DAPI; 2-g/ml final concentration) was added dur-
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ing the secondary antibody incubation. Slides were washed two times in PBS and
microscopically analyzed.
To determine whether SRA colocalized with the endoplasmic reticulum (ER),
fixed cells were incubated with monoclonal anti-Ty (1:50) and polyclonal anti-
BiP (1:4,000) (1). Goat anti-mouse Alexa Fluor 488-labeled and goat anti-rabbit
Alexa Fluor 594-labeled antibodies were added, and slides were processed as
described above. To determine SRA localization with the lysosome, cells were
stained with the anti-Ty antibody as described above and then incubated with a
monoclonal antibody to the lysosomal marker p67 (1:1,000) conjugated to Alexa
Fluor 594 (23).
To further localize SRA with the endocytic marker tomato lectin (TL; Vector
Laboratories, Burlingame, CA) (34) and TLF, we directly conjugated TL and
TLF to Alexa fluorochromes. Cells were incubated with 4 g/ml TL and/or 10 to
20 g/ml TLF for 30 min at 37°C. After incubation, the cells were put on ice,
washed, resuspended in PBSG at 4°C, smeared onto a slide, and fixed with cold
methanol. For colocalization of SRA with TL or TLF, cells were stained with
anti-Ty as described above. For localization of TLF and p67, cells were incubated
with 50 M chloroquine for 30 min before adding Alexa-conjugated TLF to a
final concentration of 20 g/ml. Cells were incubated for an additional 90 min
before being processed and stained for p67 as described above. Trypanosomes
were analyzed at a magnification of 100 with a Zeiss fluorescence microscope,
and digital images were captured with a Zeiss AxioCam video camera. The
contrast and brightness of some images were adjusted and overlaid with Adobe
Photoshop software.
RESULTS
Genotypic and phenotypic analysis of SRA-transfected T. b.
brucei. Previous studies have shown that transfection of procy-
clic T. b. brucei with SRA and subsequent transmission through
tsetse flies resulted in bloodstream-stage T. b. brucei organisms
that were resistant to normal human serum (51). The cyclical
transmission of trypanosomes through tsetse flies is difficult
due to the low transmission efficiency, variability in the ability
of T. b. brucei isolates to infect tsetse flies, and specific devel-
opmental changes in gene expression influencing the VSG
expression sites and other genes. To circumvent these prob-
lems and to directly determine if SRA and Ty epitope-tagged
SRA were sufficient to confer resistance to normal human
serum, three different isolates of bloodstream-stage T. b. brucei
were transfected with SRA and SRA-Ty. The location of the Ty
epitope within the SRA gene was not expected to disrupt the
proposed N-terminal alpha-helical domains implicated in hav-
ing a role in SRA resistance (Fig. 1A) (6, 47). Similar trans-
fections of bloodstream-stage T. b. brucei with the hemagglu-
tinin (HA) epitope fused to the amino or carboxy terminus of
SRA were reported previously (50). Genomic DNAs from
wild-type 427, transfected 427-SRA and 427-SRA-Ty, wild-
type 667, transfected 667-SRA and 667-SRA-Ty, wild-type 927,
and transfected 927-SRA and 927-SRA-Ty organisms were
analyzed for the presence of the SRA gene by PCR with prim-
ers complementary to the 5 and 3 coding sequences of SRA.
A 1.4-kb SRA product was only detected in SRA- and SRA-
Ty-transfected T. b. brucei lines and not in wild-type cells (Fig.
1B). Southern blotting confirmed single-copy integration of
SRA in the SRA and SRA-Ty transfectants (data not shown).
Control PCRs using primers specific to the 
-tubulin gene
produced the expected 0.75-kb product (Fig. 1B).
By light microscopy, no morphological differences were ob-
served between SRA-transfected and wild-type cells. In addi-
tion, cells with and without SRA reached approximately the
same cell densities and grew at the same rates, indicating that
the expression of SRA did not influence the growth character-
istics of bloodstream-stage T. b. brucei (data not shown).
Susceptibility of SRA-transfected T. b. brucei to TLF killing.
In order to determine whether transfection with SRA was suf-
ficient to confer the serum resistance phenotype, transfected
cells were incubated with increasing concentrations of TLF
(Fig. 2) or normal human serum (data not shown). The three
wild-type lines of T. b. brucei were highly susceptible to lysis by
TLF. Following SRA transfection, the three lines of T. b. brucei
showed high levels of resistance to TLF (Fig. 2). The level of
serum resistance in SRA-transfected T. b. brucei was similar to
that observed for human infectious T. b. rhodesiense (data not
shown). No difference in the level of TLF resistance was de-
tected between cells transfected with SRA alone and those
transfected with SRA-Ty (data not shown). To confirm whether
FIG. 1. Diagram of SRA gene construct and PCR analysis of transfectants. (A) Diagram of SRA gene indicating the locations of the Ty epitope
tag, signal sequence, proposed 
-helical domains, and a proposed glycosylphosphatidylinositol (GPI) anchor site. SRA-Ty was cloned into the
transfection vector pURAN, consisting of a pUC9 backbone, the neomycin resistance gene (Neor), and sequences for targeting the rRNA promoter
(ribosomal [marked with a flag]) following cleavage with the restriction enzyme SunI (25). Correct RNA processing and stability were provided
by 
-tubulin splice acceptor (
-tub sa) and 
-tubulin intergenic (
-tub ir) sequences. The Ty epitope was cloned into the SRA gene at a unique
HindIII site at 848 bp (accession no. AF097331) (2). (B) PCR amplification of SRA and tubulin genes from genomic DNAs isolated from
trypanosomes transfected with pURAN vector alone (T. b. brucei 427, 667, and 927) or with pURAN containing SRA (T. b. brucei 427-SRA,
667-SRA, and 927-SRA). The PCR products for the SRA and tubulin genes run at 1.4 kb and 0.7 kb, respectively.
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SRA-induced TLF resistance was comparable to that seen for
T. b. rhodesiense, the survival of SRA-transfected T. b. brucei
was examined at concentrations of TLF similar to those found
in human serum (1,000 U/ml) and by incubation for 24 h under
the same growth conditions in the presence of 50% human
serum. The SRA-transfected T. b. brucei lines remained viable
under these conditions (data not shown).
Early studies suggested that the VSG expressed on the sur-
faces of trypanosomes might influence their susceptibility to
normal human serum. Each of the T. b. brucei lines used in the
current studies expresses different VSG genes producing sero-
logically distinct VSG coats. Based on the T. b. brucei isolates
tested, it appears that resistance to TLF is highly dependent on
SRA expression but independent of the VSG expressed on the
trypanosome surface. The transfection of bloodstream-stage
lines of T. b. brucei directly demonstrated that expression of
the SRA gene is sufficient to confer resistance to TLF and may
lead to human infectivity.
Expression of SRA mRNA in transfected cells. SRA mRNA
is an abundant transcript in T. b. rhodesiense, representing as
much as 10% of the total cellular RNA (10, 18, 31). In order to
determine the level of SRA mRNA in transfected cells and to
compare this level with that in human infectious T. b. rhod-
esiense, total cellular RNA was isolated from T. b. brucei trans-
fected with either vector alone (427) or SRA (427-SRA) and
from a human-serum-resistant line of T. b. rhodesiense. Blots
were hybridized with probes specific for the VSG expressed by
T. b. rhodesiense (VSG-R) and the VSG-221 expressed by the
T. b. brucei 427 cell line (Fig. 3A). The amount of SRA mRNA
in human-serum-resistant T. b. rhodesiense was similar to the
level of SRA mRNA in T. b. brucei 427-SRA (Fig. 3A). The
SRA mRNA in T. b. brucei 427-SRA is approximately 460
nucleotides larger than that in T. b. rhodesiense because of
additional 5 and 3 untranslated region sequences added to
the SRA sequence in the expression vector (about 430 nucle-
otides) and the addition of the epitope tag within the gene (30
nucleotides). Equal RNA loading was confirmed by ethidium
bromide staining of the agarose gel. These results show that
while the transgenic SRA gene is expressed from the ribosomal
locus in T. b. brucei 427-SRA, the expression level of the gene
is similar to the endogenous expression level of SRA in human-
serum-resistant T. b. rhodesiense strains.
Expression of SRA in transfected T. b. brucei. Despite high
levels of SRA mRNA, the detection of SRA protein in T. b.
rhodesiense and in SRA-transfected T. b. brucei has been prob-
lematic in some cases (8, 9, 51). However, visualization of SRA
has been reported for T. b. rhodesiense cells by use of a poly-
clonal mouse antiserum raised against recombinant SRA (31).
In addition, endogenous SRA in T. b. rhodesiense as well as
recombinant SRA (rSRA) expressed in T. b. brucei was de-
tected using antibodies raised against an SRA polypeptide
(47). To examine SRA expression in transfected T. b. brucei,
total cell lysates from 3  106 trypanosomes were separated by
10% SDS-PAGE and analyzed by Coomassie staining and
Western blotting with monoclonal antibodies specific to the Ty
tag inserted into the SRA gene. Epitope-tagged proteins, mi-
grating at approximately 59 and 65 kDa, were detected in
Western blots of cell lysates of both 427-SRA and 667-SRA but
not in lysates of wild-type 427 and 667 (Fig. 3B; data for 667
and 667-SRA are not shown). The predicted size of mature
SRA is approximately 38,000 Da. While the nature of the
doublet is unknown, it may be the result of differences in
posttranslational modification of SRA. The staining patterns
observed are similar to previous Western blot results obtained
with T. b. rhodesiense extracts analyzed with anti-rSRA and
SRA-HA-transfected T. b. brucei probed with anti-HA (31,
50). As reported by others, we found that the detection of SRA
FIG. 2. Transfection of three T. b. brucei lines with SRA confers
resistance to TLF. Lysis assays were conducted with T. b. brucei trans-
fected with empty vector (427 [■], 667 [F], and 927 [Œ]) and with
SRA-Ty vector (427-SRA [], 667-SRA [E], and 927-SRA [‚]). The
percentages of trypanosomes lysed by increasing amounts of TLF
under standard assay conditions were determined following a 4-h in-
cubation at 37°C.
FIG. 3. Expression of SRA mRNA and SRA protein in transfected
T. b. brucei. (A) Northern blot analysis of total cell RNA from trans-
fected and nontransfected T. b. brucei 427. RNA samples from T. b.
brucei transfected with either empty vector (427) or SRA-containing
vector (427-SRA) or from human-serum-resistant T. b. rhodesiense [T.
b. r. (R)] were separated in 1% agarose gels and hybridized with probes
specific for the VSG mRNA from T. b. brucei 427 (VSG-221) or
wild-type T. b. rhodesiense (VSG-R) and for SRA mRNA. Ethidium
bromide staining of the agarose gel is shown in the top panel. (B) Pro-
tein gel and Western blot of T. b. brucei 427. The Coomassie-stained
gel and Western blot analysis show results for protein extracts from T.
b. brucei transfected with vector alone (427) or with SRA (427-SRA-
Ty). The Western blot was probed with antibodies to the Ty epitope,
and proteins of approximately 59 and 65 kDa were detected in extracts
from T. b. brucei 427-SRA-Ty (arrows).
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by Western blot analysis was variable, suggesting that SRA
may be highly susceptible to proteolytic degradation while cell
extracts are prepared for analysis.
Cellular localization of SRA and TLF in T. b. brucei 427-
SRA-Ty. We determined the cellular localization of SRA in T.
b. brucei 427-SRA-Ty by immunofluorescence microscopy, us-
ing a monoclonal antibody against the Ty epitope. This anti-
body is highly specific for the Ty epitope and does not react
with wild-type T. b. brucei 427 proteins by either Western
blotting or immunofluorescence analysis. T. b. brucei 427-
SRA-Ty cells were fixed, permeabilized, and incubated with
anti-Ty. SRA-Ty was visible within cytoplasmic vesicles located
mainly between the kinetoplasts and the nuclei of T. b. brucei
427-SRA cells (Fig. 4C, G, and K). Only minor cell surface
labeling was observed, indicating that SRA in transfected T. b.
brucei is mainly localized to intracellular compartments.
We were concerned that the expression of SRA-Ty from the
ribosomal locus in T. b. brucei might result in aggregation
within the ER or targeting to the lysosome for degradation. T.
b. brucei 427-SRA-Ty cells were double stained for SRA (anti-
Ty) and the ER (anti-BiP), endocytic compartments (Alexa-
conjugated TL), or the lysosome (anti-p67). Double labeling of
T. b. brucei 427-SRA-Ty with anti-BiP and anti-Ty revealed a
distinctive ER staining pattern with the BiP antibody (red),
with little colocalization with SRA-Ty (green; Fig. 4A to D).
To determine whether SRA was located in endosomes or the
lysosome, T. b. brucei 427-SRA-Ty cells were incubated with
Alexa Fluor 594-labeled TL (red) for 30 min at 37°C to allow
uptake and lysosomal targeting of the ligand. Cells were then
fixed and incubated with anti-Ty (green). Under these condi-
tions, TL accumulated largely in the trypanosome lysosome
(Fig. 4F), and to a limited extent, in endosomes located nearer
the flagellar pocket (green; Fig. 5C and G). While SRA-Ty
localized to the region between the kinetoplast and the nu-
cleus, SRA-Ty staining did not overlap with TL staining (Fig.
4E to H). To directly address lysosomal localization, we stained
cells with an antibody to p67 (red) and found that SRA-con-
taining vesicles (green) did not significantly overlap with local-
ization of the lysosomal membrane protein p67 (Fig. 4I to L).
This pattern suggests that SRA-Ty is predominately nonlyso-
somal.
TLF killing of T. b. brucei requires lysosomal localization
and subsequent acidification (20, 26). T. b. brucei 427 was
incubated with TLF conjugated with Alexa Fluor 594 (red) and
TL conjugated with Alexa Fluor 488 (green) for 30 min at
37°C. Under these conditions, both TLF and TL colocalized
mainly to the lysosomes of wild-type cells (Fig. 5A to D). These
results are consistent with previous studies that localized TLF
to lysosomes of other isolates of T. b. brucei (20, 44). In con-
trast, TLF did not colocalize with the endocytic marker TL in
T. b. brucei 427-SRA-Ty cells (Fig. 5E to H). After 30 min,
small TLF-containing vesicles were seen close to the flagellar
pocket (Fig. 5F).
Once we saw that TLF did not seem to be trafficking by its
normal endocytic pathway in the SRA-expressing cells, we
asked whether TLF could be concentrated in the lysosome in
the presence of chloroquine. Previous studies have shown that
chloroquine blocks lysosome acidification and prevents the
degradation of endocytosed proteins (44). Cells were treated
with chloroquine for 30 min before incubation with TLF for 90
min in an attempt to force TLF into the lysosome. As expected,
in wild-type T. b. brucei, TLF accumulated and colocalized with
FIG. 4. Cellular localization of SRA in T. b. brucei 427-SRA-Ty.
Immunofluorescence analysis was done with cells treated with antibod-
ies to Ty epitope-tagged SRA and to the ER marker BiP (A to D), the
endocytic marker TL (E to H), or the lysosomal marker p67 (I to L).
The positions of the nucleus (N) and the kinetoplast (K) were visual-
ized by staining with DAPI (blue). (A, E, and I) Cells visualized by
bright-field (BF) microscopy overlaid with DAPI-stained DNA.
(B) Cell stained with anti-BiP (red). (F) Cell following uptake of
Alexa-conjugated TL (red). (J) Cell stained with anti-p67 (red). (C, G,
and K) Cells stained for SRA with anti-Ty (green). (D, H, and L)
Overlays of images of cells stained for DNA/BiP/SRA, DNA/TL/SRA,
or DNA/p67/SRA, respectively.
FIG. 5. Cellular localization of TL and TLF taken up by wild-type
T. b. brucei 427 (A to D) and T. b. brucei 427-SRA-Ty (E to H). The
positions of the nucleus and the kinetoplast were visualized by staining
with DAPI (blue). (A and E) Cells visualized by bright-field (BF)
microscopy overlaid with DAPI-stained DNA. Cells are shown follow-
ing incubation with Alexa-conjugated TLF (red) (B and F) or Alexa-
conjugated TL (green) (C and G). (D and H) Overlays of images of
cells stained for DNA and visualized for the appearance of Alexa-
conjugated TLF and TL. The arrows in panel D indicate the sites of
TLF and TL colocalization in wild-type T. b. brucei.
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the lysosomal marker p67 (Fig. 6A to D). However, in the T. b.
brucei 427-SRA-Ty cells, TLF localization was quite different.
TLF did not localize with p67 and accumulated in nonlysoso-
mal vesicles (Fig. 6E to H). Similar results were obtained when
non-chloroquine-treated cells were examined (data not
shown). Based on these results, we conclude that the intracel-
lular trafficking of TLF is altered in T. b. brucei 427-SRA-Ty
and that the expression of SRA may prevent TLF from reach-
ing the lysosome, the site of trypanolytic activity.
SRA and TLF colocalize in T. b. brucei 427-SRA-Ty. The
essential nature of SRA expression in human-serum-resistant
T. b. brucei suggests that SRA and TLF may interact with one
another directly. In fact, studies have shown that SRA directly
interacts with apoL-I, one of the trypanolytic components of
TLF (47). To examine whether SRA and TLF are contained in
the same cellular compartments, we incubated T. b. brucei
427-SRA-Ty with Alexa Fluor 594-conjugated TLF and subse-
quently stained the cells for SRA using the Ty antibody. Flu-
orescence microscopy showed that TLF (red) and SRA-Ty
(green) overlap in their subcellular distributions (Fig. 7A to
H). TLF and SRA colocalized to a subpopulation of small
cytosolic vesicles in SRA-transfected T. b. brucei, but neither
was found in the lysosome. We observed many SRA-containing
vesicles without TLF, but few vesicles containing TLF alone,
without SRA, were detected (Fig. 7D and H). These findings
are consistent with a proposed mechanism of resistance to TLF
resulting from reduced targeting of TLF to the lysosome and
with the idea that the association of SRA and TLF is required
for resistance (19).
DISCUSSION
Initial studies using subtractive hybridization methods sug-
gested that human-serum-resistant and -sensitive African try-
panosomes might differ by the expression of a single gene (27).
This possibility was tested in an elegant series of transfection
experiments, in which the SRA gene from T. b. rhodesiense was
introduced into a human-serum-susceptible line of T. b. brucei
and was found to be sufficient to confer resistance (51). These
studies relied on transfection of an insect-borne developmental
stage of T. b. brucei and subsequent transmission through the
tsetse fly prior to analysis of transfectants. This strategy,
though certainly successful, is both cumbersome and poten-
tially prone to artifacts due to changes in gene expression
unrelated to the transgene. In this paper and elsewhere, direct
transfection of bloodstream-stage T. b. brucei with SRA was
shown to render the parasites resistant to both TLF and nor-
mal human serum (50). Transfected T. b. brucei cells express
the SRA transgene at high levels, resulting in steady-state
amounts of the SRA mRNA that are similar to those detected
in human infectious T. b. rhodesiense. Using antibodies against
the Ty epitope, we examined the intracellular distribution of
SRA in T. b. brucei 427-SRA-Ty and found it to be largely
localized to small cytoplasmic vesicles between the flagellar
pocket and the nucleus. The incubation of T. b. brucei 427-
SRA-Ty with TLF resulted in the accumulation of TLF in
SRA-containing vesicles, but TLF was not seen in the trypano-
some lysosome. Since the acidified lysosome is the site of
action for TLF, this altered intracellular trafficking may be the
primary cause of TLF and human serum resistance in SRA-
transfected cells.
In several studies, data have shown that while SRA mRNAs
are abundant in both T. b. rhodesiense and SRA-transfected T.
b. brucei, the detection of SRA has been problematic (31, 51).
More recently however, antibodies to SRA have been success-
fully used to detect endogenous SRA in T. b. rhodesiense by
immunofluorescence and rSRA expressed in T. b. brucei by
Western blotting (47). The variability in SRA detection may be
a consequence of rapid intracellular degradation, the secretion
of newly synthesized SRA, or accelerated turnover of the pro-
tein during parasite isolation. While intracellular SRA-Ty was
consistently observed by immunofluorescence microscopy, we
found that the detection of Ty-tagged SRA in protein extracts
was highly variable. In comparison to one study, our results
with T. b. brucei 427-SRA-Ty differ from those obtained for T.
b. rhodesiense in a potentially important way (31). In that study,
SRA was detected both in cytoplasmic vesicles, similar in dis-
tribution to those reported here, and on the surfaces of the
FIG. 6. Cellular localization of TLF relative to p67 in T. b. brucei
427 (A to D) and T. b. brucei 427-SRA-Ty (E to H) in the presence of
chloroquine. The positions of the nucleus and the kinetoplast were
visualized by staining with DAPI (blue). (A and E) Cells visualized by
bright-field (BF) microscopy overlaid with DAPI staining. (B and F)
Cells incubated with Alexa-conjugated TLF (red). (C and G) Cells
stained with anti-p67 (green). (D and H) Overlays of images of cells
incubated with Alexa-conjugated TLF and stained for DNA and p67.
FIG. 7. Colocalization of TLF-1 and SRA in T. b. brucei 427-SRA-
Ty. The positions of the nucleus and the kinetoplast were visualized by
staining with DAPI (blue) (A to H). (A and E) Cells visualized by
bright-field (BF) microscopy overlaid with DAPI staining of the nu-
cleus and kinetoplast. (B and F) Cells incubated with Alexa-conjugated
TLF (red). (C and G) Cells stained with anti-Ty (green) to visualize
SRA. (D and H) Overlaid images of cells treated with Alexa-conju-
gated TLF and stained for DNA and SRA.
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trypanosomes. It is possible that the cell surface reactivity was
simply a consequence of cross-reactivity of the polyclonal
mouse antiserum against SRA with the VSG. This is a partic-
ular concern since SRA is a member of the VSG gene family
and shares characteristics with other trypanosome cell surface
proteins (6, 31). Alternatively, the amounts of SRA present on
the cell surface in different trypanosome lines may vary. Re-
gardless, the significance of the cell surface-associated SRA is
questionable, since little or no SRA was found on the surfaces
of T. b. brucei 427-SRA-Ty cells yet they were highly resistant
to both TLF-1 and human serum. Other labs have also shown
that the localization of endogenous SRA in T. b. rhodesiense is
primarily intracellular (47). In this paper, we showed that
SRA-Ty localizes to an intracellular, nonlysosomal, vesicular
location in transfected T. b. brucei.
We were concerned that high-level expression of SRA might
result in aberrant intracellular localization. Transgenes are
often expressed at abnormal levels due to the use of heterol-
ogous promoters. In our construct, SRA expression is driven
from a constitutively active rRNA polymerase I promoter
known to mediate high levels of mRNA synthesis in African
trypanosomes (25, 41). The 5 and 3 untranslated regions were
derived from tubulin sequences, which contribute posttran-
scriptionally to the stability of mRNAs in both bloodstream
and procyclic forms. Previous studies have shown that SRA
mRNA is an abundant transcript in both wild-type T. b. rhod-
esiense and transfected T. b. brucei, representing as much as 5
to 10% of the total mRNA (31, 51). This is comparable to the
levels of VSG mRNA in African trypanosomes. We found that
the amount of SRA mRNA in our transfectants was similar to
the level of SRA mRNA expression in T. b. rhodesiense. Since
SRA in T. b. brucei 427-SRA-Ty confers resistance to human
serum and the amount of SRA mRNA is similar to that in
wild-type T. b. rhodesiense, it seems likely that the SRA-con-
taining cytosolic vesicles revealed by immunofluorescence mi-
croscopy are the primary sites of SRA activity.
The subcellular localization of SRA and how it prevents
TLF from reaching the lysosome may provide a better under-
standing of both the function of SRA and the endocytic path-
ways of trypanosomes. This is in contrast to the proposed site
of SRA activity being at the lysosome, where it interacts with
apoL-1 (47). However, an important difference between these
studies is the use of purified human HDLs containing both Hpr
and apoL-1 in our studies rather than purified and recombi-
nant apoL-1. The uptake and trafficking of native TLF and its
interaction with SRA may differ from that of recombinant
apoL-I. Endocytosis in trypanosomes shares many character-
istics with endocytosis in other eukaryotic organisms but also
exhibits several unique features, including developmental reg-
ulation, selective trafficking of proteins from the flagellar
pocket, and the potential routing of resident lysosomal pro-
teins through the flagellar pocket prior to localization to the
lysosome (35). Vesicular trafficking between organelles occurs
through the fusion of donor and specific acceptor membranes.
This process is highly regulated and ensures proper direction-
ality in protein sorting and packaging. Monomeric GTPases of
the Rab family play a pivotal role in the control of membrane
fusion and vesicle trafficking. Several T. brucei Rab proteins
have now been identified that localize to specific subcellular
compartments (14–17, 28, 35). The availability of antibodies to
the T. b. brucei Rab proteins makes it possible to determine
whether the cytosolic vesicles containing SRA and TLF are
part of a vesicle recycling pathway.
Although we have shown that SRA confers human serum
resistance when transfected into bloodstream-stage T. b. brucei
and that SRA and TLF colocalize within cytoplasmic vesicles,
the mechanism of SRA function is still unknown. One pro-
posed mechanism is that inhibition may depend on interactions
between SRA and apoL-I in the lysosome (47, 48). However,
we previously showed that TLF was not targeted to the lyso-
some in T. b. rhodesiense, whereas a naturally occurring hu-
man-serum-sensitive variant of T. b. rhodesiense transported
TLF to the lysosome prior to cell lysis (19). The distributions of
TLF in T. b. rhodesiense and in T. b. brucei 427-SRA-Ty appear
to be somewhat different. In contrast to the localization of TLF
to small cytoplasmic vesicles in T. b. brucei 427-SRA-Ty, TLF
was largely localized at or near the flagellar pocket of T. b.
rhodesiense (19). Therefore, it remains possible that SRA can
influence TLF uptake and lysosomal trafficking at either the
flagellar pocket, where receptor-mediated endocytosis ini-
tiates, or at later steps in the endocytic pathway.
Regardless of the precise role of SRA, we have shown that
SRA expression is sufficient to confer resistance to TLF and
normal human serum in T. b. brucei bloodstream-stage try-
panosomes. Furthermore, we have shown that SRA is respon-
sible for the rerouting of TLF within the trypanosome endo-
cytic pathway, with the majority of the TLF becoming
associated with nonlysosomal, SRA-containing vesicles. Future
experiments will address whether SRA alters TLF localization
by either recycling it out of the cell or directing it to a cellular
compartment where TLF degradation is accelerated. The elu-
cidation of mechanisms of TLF resistance could lead to the
development of inhibitors of the SRA-mediated resistance
pathway, thereby increasing the susceptibility of T. b. rhod-
esiense-mediated human sleeping sickness trypanosomes to
TLF and thus leading to novel treatment of the disease.
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